Aarhus Universitets segl

English

Du er her: AU » Om AU » Organisation » Kenneth Jensen » Publikationer » IMRT – Biomarkers for dose escalation, dose de-escalation...

Om AU

Kenneth Jensen

IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Standard

IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. / Andreassen, C. N.; Eriksen, J. G.; Jensen, K. et al.
I: Oral Oncology, Bind 86, 01.11.2018, s. 91-99.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Harvard

Andreassen, CN, Eriksen, JG, Jensen, K, Hansen, CR, Sørensen, BS, Lassen, P, Alsner, J, Schack, LMH, Overgaard, J & Grau, C 2018, 'IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer', Oral Oncology, bind 86, s. 91-99. https://doi.org/10.1016/j.oraloncology.2018.09.001

APA

Andreassen, C. N., Eriksen, J. G., Jensen, K., Hansen, C. R., Sørensen, B. S., Lassen, P., Alsner, J., Schack, L. M. H., Overgaard, J., & Grau, C. (2018). IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. Oral Oncology, 86, 91-99. https://doi.org/10.1016/j.oraloncology.2018.09.001

CBE

Andreassen CN, Eriksen JG, Jensen K, Hansen CR, Sørensen BS, Lassen P, Alsner J, Schack LMH, Overgaard J, Grau C. 2018. IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. Oral Oncology. 86:91-99. https://doi.org/10.1016/j.oraloncology.2018.09.001

MLA

Andreassen, C. N. et al. "IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer". Oral Oncology. 2018, 86. 91-99. https://doi.org/10.1016/j.oraloncology.2018.09.001

Vancouver

Andreassen CN, Eriksen JG, Jensen K, Hansen CR, Sørensen BS, Lassen P et al. IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. Oral Oncology. 2018 nov. 1;86:91-99. doi: 10.1016/j.oraloncology.2018.09.001

Author

Andreassen, C. N. ; Eriksen, J. G. ; Jensen, K. et al. / IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. I: Oral Oncology. 2018 ; Bind 86. s. 91-99.

Bibtex

@article{8fba50f9c34443109ccc8dd174184653,
title = "IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer",
abstract = "Radiotherapy (RT) is an integral component in the management of head and neck cancer. Despite progress in several respects, a noteworthy proportion of the treated patients do not achieve complete response after RT. Regardless of novel dose delivery technologies, RT for head and neck cancer is still associated with acute as well as late toxicity. These challenges could potentially be addressed by means of personalized treatment. In this paper, we discuss the possibilities for dose escalation, dose de-escalation and allocation to systemic concomitant treatment based on prognostic and predictive markers for tumor control as well as predictive markers for normal tissue radiosensitivity.",
keywords = "Cancer stem cells, Head and neck cancer, HPV, Hypoxia, p16, Personalized medicine, Radiogenomics, Radiotherapy, SNP",
author = "Andreassen, {C. N.} and Eriksen, {J. G.} and K. Jensen and Hansen, {C. R.} and S{\o}rensen, {B. S.} and P. Lassen and J. Alsner and Schack, {L. M.H.} and J. Overgaard and C. Grau",
year = "2018",
month = nov,
day = "1",
doi = "10.1016/j.oraloncology.2018.09.001",
language = "English",
volume = "86",
pages = "91--99",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Pergamon Press",

}

RIS

TY - JOUR

T1 - IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer

AU - Andreassen, C. N.

AU - Eriksen, J. G.

AU - Jensen, K.

AU - Hansen, C. R.

AU - Sørensen, B. S.

AU - Lassen, P.

AU - Alsner, J.

AU - Schack, L. M.H.

AU - Overgaard, J.

AU - Grau, C.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Radiotherapy (RT) is an integral component in the management of head and neck cancer. Despite progress in several respects, a noteworthy proportion of the treated patients do not achieve complete response after RT. Regardless of novel dose delivery technologies, RT for head and neck cancer is still associated with acute as well as late toxicity. These challenges could potentially be addressed by means of personalized treatment. In this paper, we discuss the possibilities for dose escalation, dose de-escalation and allocation to systemic concomitant treatment based on prognostic and predictive markers for tumor control as well as predictive markers for normal tissue radiosensitivity.

AB - Radiotherapy (RT) is an integral component in the management of head and neck cancer. Despite progress in several respects, a noteworthy proportion of the treated patients do not achieve complete response after RT. Regardless of novel dose delivery technologies, RT for head and neck cancer is still associated with acute as well as late toxicity. These challenges could potentially be addressed by means of personalized treatment. In this paper, we discuss the possibilities for dose escalation, dose de-escalation and allocation to systemic concomitant treatment based on prognostic and predictive markers for tumor control as well as predictive markers for normal tissue radiosensitivity.

KW - Cancer stem cells

KW - Head and neck cancer

KW - HPV

KW - Hypoxia

KW - p16

KW - Personalized medicine

KW - Radiogenomics

KW - Radiotherapy

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=85053483801&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2018.09.001

DO - 10.1016/j.oraloncology.2018.09.001

M3 - Journal article

C2 - 30409326

AN - SCOPUS:85053483801

VL - 86

SP - 91

EP - 99

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -